Blinatumomab – July 2026

  • Brand names:
    • Blincyto®
  • Pharmaceutical Company:
    • AMGEN AUSTRALIA PTY LIMITED
  • Condition/Indication: Acute lymphoblastic leukaemia (ALL) Precursor B-cell ALL (Pre-B-cell ALL)
  • Meeting Date: July 2026
Public Summary Documents
Last updated
13 November 2026